Stock listing
LSE:0HB0 Agios Pharmaceuticals, Inc. Share Price
UK listing (LSE) of Agios Pharmaceuticals, Inc. · home listing NASDAQ:AGIO
Follow Agios Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · LSE:0HB0
$28.35 USD -1.60 (-5.3%)
Close on Nov 20, 2026
- Day range
- $27.56 – $28.47 USDNov 20, 2026
- Volume
- 63 sharesNov 20, 2026
- Traded on an average day
- $11,326 USDMedian day 102 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AGIO · Home | $27.60 USD | -2.08 (-7.0%) | 776,163 | $28.01 | $29.14 | $27.43 | $29.68 | Close on Nov 20, 2026 |
| LSE:0HB0 | $28.35 USD | -1.598 (-5.3%) | 63 | $27.56 | $28.47 | $27.56 | $29.95 | Close on Nov 20, 2026 |
| Frankfurt:8AP | €25.60 EUR | -1.60 (-5.9%) | — | €25.60 | €25.60 | €25.60 | €27.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0HB0 · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $29.33 | +0.89 | +3.1% | $28.83 | $29.33 | $28.00 | 228 | |
| $28.44 | -2.95 | -9.4% | $31.70 | $31.70 | $28.44 | 86 | |
| $31.39 | +0.09 | +0.3% | $31.50 | $31.50 | $30.97 | 3 | |
| $31.30 | +0.63 | +2.1% | $30.20 | $31.31 | $30.16 | 820 | |
| $30.67 | +0.24 | +0.8% | $31.50 | $31.50 | $30.43 | 203 | |
| $30.43 | -6.475 | -17.5% | $37.23 | $37.23 | $29.97 | 4,287 | |
| $36.91 | -1.175 | -3.1% | $39.04 | $39.04 | $36.78 | 536 | |
| $38.08 | +0.52 | +1.4% | $37.51 | $38.36 | $36.96 | 201 | |
| $37.56 | +0.765 | +2.1% | $37.35 | $37.56 | $36.50 | 232 | |
| $36.80 | -0.385 | -1.0% | $37.70 | $37.92 | $36.32 | 166 | |
| $37.18 | +0.72 | +2.0% | $37.19 | $37.19 | $36.24 | 53 | |
| $36.46 | -0.91 | -2.4% | $37.18 | $37.50 | $36.00 | 107 | |
| $37.37 | +0.87 | +2.4% | $37.00 | $37.42 | $35.74 | 302 | |
| $36.50 | +2.606 | +7.7% | $34.90 | $36.60 | $34.45 | 575 | |
| $33.89 | +2.194 | +6.9% | $32.54 | $34.43 | $32.48 | 743 | |
| $31.70 | -0.30 | -0.9% | $32.93 | $32.93 | $31.70 | 4 | |
| $32.00 | +1.17 | +3.8% | $32.35 | $32.35 | $31.74 | 164 | |
| $30.83 | +0.57 | +1.9% | $30.26 | $30.83 | $30.02 | 166 | |
| $30.26 | -1.16 | -3.7% | $31.01 | $31.01 | $30.10 | 1,177 | |
| $31.42 | -0.53 | -1.7% | $31.50 | $32.50 | $31.00 | 183 | |
| $31.95 | +0.02 | +0.1% | $31.90 | $32.75 | $31.55 | 18 | |
| $31.93 | +0.106 | +0.3% | $31.91 | $31.93 | $31.18 | 35 | |
| $31.82 | +0.034 | +0.1% | $31.85 | $32.27 | $31.61 | 660 | |
| $31.79 | +0.469 | +1.5% | $31.45 | $31.79 | $30.96 | 65 | |
| $31.32 | -0.607 | -1.9% | $32.50 | $32.50 | $30.99 | 33 | |
| $31.93 | -0.902 | -2.7% | $33.02 | $33.02 | $31.71 | 34 | |
| $32.83 | -0.78 | -2.3% | $33.50 | $33.50 | $32.83 | 17 | |
| $33.61 | +0.60 | +1.8% | $33.67 | $34.10 | $33.43 | 5 | |
| $33.01 | +0.21 | +0.6% | $34.00 | $34.00 | $32.78 | 31 | |
| $32.80 | -0.311 | -0.9% | $32.67 | $32.80 | $32.00 | 21 | |
| $33.11 | -0.059 | -0.2% | $33.50 | $33.50 | $32.73 | 332 | |
| $33.17 | -1.08 | -3.2% | $35.00 | $35.00 | $31.71 | 263 | |
| $34.25 | -0.78 | -2.2% | $34.85 | $34.85 | $34.25 | 108 | |
| $35.03 | +0.78 | +2.3% | $34.25 | $35.03 | $33.84 | 565 | |
| $34.25 | +1.16 | +3.5% | $33.56 | $34.25 | $33.56 | 14 | |
| $33.09 | -0.93 | -2.7% | $33.12 | $33.14 | $33.09 | 32 | |
| $34.02 | +1.415 | +4.3% | $33.79 | $34.02 | $33.65 | 49 | |
| $32.61 | -0.745 | -2.2% | $33.00 | $33.00 | $32.61 | 141 | |
| $33.35 | -0.69 | -2.0% | $34.78 | $34.99 | $33.35 | 33 | |
| $34.04 | +0.65 | +1.9% | $34.04 | $34.04 | $34.04 | 4 | |
| $33.39 | -1.26 | -3.6% | $34.26 | $34.26 | $33.39 | 31 | |
| $34.65 | +1.12 | +3.3% | $33.70 | $35.27 | $33.70 | 300 | |
| $33.53 | +0.365 | +1.1% | $32.23 | $33.53 | $32.23 | 102 | |
| $33.17 | -0.185 | -0.6% | $32.95 | $33.17 | $32.95 | 54 | |
| $33.35 | -1.00 | -2.9% | $33.84 | $34.50 | $33.27 | 149 | |
| $34.35 | +0.36 | +1.1% | $34.76 | $34.84 | $33.76 | 29 | |
| $33.99 | +0.79 | +2.4% | $34.00 | $34.00 | $33.75 | 44 | |
| $33.20 | -0.44 | -1.3% | $33.31 | $33.99 | $33.05 | 12 | |
| $33.64 | -1.027 | -3.0% | $34.14 | $34.14 | $33.44 | 91 | |
| $34.67 | +0.617 | +1.8% | $33.50 | $34.67 | $33.50 | 902 | |
| $34.05 | +0.06 | +0.2% | $33.84 | $34.05 | $33.84 | 3 | |
| $33.99 | +0.99 | +3.0% | $33.11 | $34.17 | $32.84 | 4,115 | |
| $33.00 | -0.21 | -0.6% | $32.50 | $33.00 | $32.50 | 52 | |
| $33.21 | -0.68 | -2.0% | $33.50 | $34.08 | $33.21 | 18 | |
| $33.89 | -1.66 | -4.7% | $35.29 | $35.29 | $33.83 | 332 |
- Ticker
- LSE:0HB0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · Nov 5, 2026
Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jul 30, 2026
Q2 2026 Earnings Presentation
Earnings · 26 slides
Latest news
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $28.44 (-9.4%) on Nov 5, 2026
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Nov 4, 2026
Closed $31.39 (+0.3%) on Nov 4, 2026
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
Oct 30, 2026
Closed $30.43 (-17.5%) on Oct 30, 2026
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8: 00 a.m. ET
Oct 8, 2026
Closed $31.93 (+0.3%) on Oct 8, 2026
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Jul 30, 2026
Closed $33.26 (-6.0%) on Jul 30, 2026
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Jul 21, 2026
Closed $37.80 (-5.3%) on Jul 21, 2026
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Jul 7, 2026
Closed $42.89 (+15.6%) on Jul 7, 2026
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8: 00 a.m. ET
Jun 29, 2026
Closed $37.72 (+2.0%) on Jun 29, 2026
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Jun 13, 2026
Closed $30.91 (+3.8%) on Jun 15, 2026
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Jun 1, 2026
Closed $28.26 (-5.7%) on Jun 1, 2026
Agios Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 25 in the last 12 months · 221 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 5, 2026
- Decks
- 38 decks · latest Jul 30, 2026
Where Agios Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AGIO · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A1W2RM | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1W2RM | LS Exchange | Germany | EUR |
| gettex:8AP | gettex | Germany | EUR |
| LSE:0HB0 · This page | LSE | United Kingdom | USD |
| BMV:AGIO | BMV | Mexico | MXN |
| Tradegate:8AP | Tradegate | Germany | EUR |
| BOATS:AGIO | BOATS | United States | USD |
| BIVA:AGIO | BIVA | Mexico | MXN |
| BX Swiss:8AP | BX Swiss | Switzerland | CHF |
| Dusseldorf:8AP | Dusseldorf | Germany | EUR |
| Frankfurt:8AP | Frankfurt | Germany | EUR |
| Munich:8AP | Munich | Germany | EUR |
| Stuttgart:8AP | Stuttgart | Germany | EUR |
Valuation
EV/sales 7.4× against a median of 3.5×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.05B USD
- P/E
- Loss
- EV/sales
- 7.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- 91.9%
- Operating margin
- −297.7%
- Net margin
- −264.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.10
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. · NASDAQ:AGIO | US$1.65B | US$1.05B | n/a | 7.4× | n/a | 1.7× | −264.8% | 0.0× | 1.10 |
| Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE | US$1.68B | US$2.60B | n/a | 3.6× | n/a | n/a | −71.8% | n/a | 1.35 |
| Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN | US$1.67B | US$1.85B | 3.7× | 1.4× | n/a | n/a | 32.9% | n/a | 0.67 |
| Caplin Point Laboratories Limited · NSE:CAPLIPOINT | US$1.66B | US$1.56B | 23.2× | 6.3× | 18.1× | 4.3× | 29.1% | 0.0× | n/a |
| AstraZeneca Pharma India Limited · NSE:ASTRAZEN | US$1.66B | US$1.60B | 86.8× | 5.7× | 59.3× | 17.5× | 6.8% | 0.0× | n/a |
| Hugel, Inc. · KRX:145020 | US$1.66B | US$1.21B | 14.1× | 3.4× | 7.1× | 2.1× | 32.9% | 0.0× | n/a |
| Faes Farma, S.A. · BME:FAE | US$1.65B | US$1.93B | 11.0× | 1.7× | 5.8× | 1.9× | 13.1% | 0.5× | n/a |
| Consun Pharmaceutical Group Ltd. · HKEX:1681 | US$1.64B | US$1.06B | 10.1× | 2.1× | 5.6× | 2.3× | 31.6% | 0.1× | n/a |
| BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166 | US$1.63B | US$1.68B | 106× | 8.3× | n/a | 3.5× | 7.6% | 0.5× | n/a |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A · SZSE:002399 | US$1.62B | US$986.2M | 57.0× | 1.3× | n/a | 0.9× | 3.7% | 0.0× | n/a |
| NATCO Pharma Limited · NSE:NATCOPHARM | US$1.62B | US$1.62B | 13.1× | 4.3× | 14.2× | 1.6× | 32.8% | 0.0× | n/a |
| Median of the others | US$1.65B | US$1.61B | 14.1× | 3.5× | 10.7× | 2.2× | 21.1% | 0.0× | 1.01 |
Forecasts
7 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 46.11 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.56 · 7 analysts
- Revenue, year to Dec 2026
- 185.3M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brian Goff | Chief Executive Officer |
| Cecilia Jones | Chief Financial Officer |
| Jim Burns | Chief Legal Officer |
| Contacts:Investor ContactMorgan Sanford | Vice President, Investor Relations Agios |
| Ellen Lopresti | Chief People Officer |
| Krishnan Viswanadhan | Chief Strategy and Operations Officer |
| Sarah Gheuens | Chief Medical Officer, Head of R&D |
| Tsveta Milanova | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Catherine Owen | Independent Director |
| Cynthia Smith | Independent Director |
| David Scadden | Independent Director |
| Jackie Fouse | Independent Director |
| Jay Backstrom | Independent Director |
| Jeffrey Capello | Independent Director |
| Kaye Foster | Independent Director |
| Maykin Ho | Independent Director |
| Rahul Ballal | Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2025 Earnings Call | Thu, Jul 31, 2025 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2025 Earnings Call | Thu, May 01, 2025 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2024 Earnings Call | Thu, Oct 31, 2024 · 8:00 AM ET | Replay |
| Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 8:00 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −9.9% |
| Q2 2026 | Jul 30, 2026 · Before open | −6.5% |
| Q1 2026 | Apr 29, 2026 · Before open | +13.1% |
| Q4 2025 | Feb 12, 2026 | +0.9% |
| Q3 2025 | Oct 30, 2025 · Before open | +2.9% |
| Q2 2025 | Jul 31, 2025 · Before open | −0.8% |
| Q1 2025 | May 1, 2025 · Before open | +4.2% |
| Q4 2024 | Feb 13, 2025 · Before open | +1.5% |
| Q3 2024 | Oct 31, 2024 · Before open | −4.0% |
| Q2 2024 | Aug 1, 2024 · Before open | −4.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +2.7% |
| Q4 2023 | Feb 15, 2024 · Before open | +3.5% |
| Q3 2023 | Nov 2, 2023 · Before open | −1.4% |
| Q2 2023 | Aug 3, 2023 · Before open | −0.1% |
| Q1 2023 | May 4, 2023 · Before open | +7.7% |
| Q4 2022 | Feb 23, 2023 · Before open | −1.7% |
| Q3 2022 | Nov 3, 2022 · Before open | −5.3% |
| Q2 2022 | Aug 4, 2022 · Before open | +14.7% |
| Q1 2022 | May 5, 2022 · Before open | −4.7% |
| Q4 2021 | Feb 24, 2022 · Before open | +5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 26 slides | Jul 30, 2026 |
| Technical Presentation (June 2026) | Technical | 18 slides | June 2026 |
| EHA 2026 Congress | Conference | 24 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 25 slides | Apr 29, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Feb 12, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 33 slides | Jan 14, 2026 |
| Technical Presentation (November 2025) | Technical | 26 slides | November 2025 |
| Q3 2025 Earnings Presentation | Earnings | 28 slides | Oct 30, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 27 slides | Jul 31, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 38 slides | May 1, 2025 |
All 38 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.0M | 36.5M | 26.8M | 14.2M | 0 | 0 | 117.9M | 94.4M | 43.0M | 69.9M |
| Cost of revenue | 6.34M | 4.17M | 2.88M | 1.70M | 0 | 0 | 1.32M | 1.40M | 0 | 0 |
| Gross profit | 42.5M | 32.3M | 17.3M | 12.5M | -18.8M | -18.8M | 116.6M | 93.0M | 43.0M | 69.9M |
| Research and development | 339.5M | 301.3M | 295.5M | 279.9M | 257.0M | 220.8M | 214.3M | 341.3M | 292.7M | 220.2M |
| Selling, general and administrative | 180.3M | 156.8M | 119.9M | 121.7M | 121.4M | 115.1M | 102.0M | 114.1M | 71.1M | 50.7M |
| Operating income | -472.1M | -425.7M | -391.5M | -389.0M | -378.4M | -335.9M | -316.3M | -362.5M | -320.8M | -201.0M |
| Depreciation and amortization | 5.20M | 5.70M | 6.60M | 8.40M | 8.80M | 9.40M | 8.09M | 7.17M | 6.43M | 5.71M |
| EBITDA | -466.9M | -420.0M | -384.9M | -380.6M | -369.6M | -326.5M | -308.2M | -355.3M | -314.4M | -195.3M |
| Interest expense | 12.8M | 836.0K | 17.8M | 14.9M | 16.5M | 6.12M | 2.51M | |||
| Income before tax | -413.8M | 718.0M | -352.1M | -231.8M | -356.5M | -329.3M | -301.4M | -346.0M | -314.7M | -198.5M |
| Income tax | -1.02M | 44.2M | 0 | 0 | -1.98B | 7.85M | 0 | 0 | 0 | 0 |
| Net income | -412.8M | 673.7M | -352.1M | -231.8M | 1.60B | -327.4M | -411.5M | -346.0M | -314.7M | -198.5M |
| Earnings per share, basic | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 |
| Earnings per share, diluted | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | -6.03 | -6.75 | -5.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 89.1M | 76.2M | 88.2M | 139.3M | 203.1M | 127.4M | 80.9M | 70.5M | 102.7M | 160.8M |
| Short-term investments | 765.3M | 817.5M | 688.7M | 643.9M | 816.9M | 445.5M | 483.9M | 514.8M | 321.2M | 380.6M |
| Receivables | 10.6M | 4.11M | 2.81M | 2.21M | 4.38M | 25.4M | 15.3M | 10.4M | 3.84M | 8.31M |
| Inventory | 32.9M | 27.6M | 19.1M | 8.49M | 0 | 14.7M | 7.33M | 869.0K | 0 | -32.3M |
| Current assets | 942.1M | 965.6M | 833.8M | 832.8M | 1.06B | 636.7M | 611.7M | 613.8M | 445.3M | 559.9M |
| Property, plant and equipment | 10.8M | 11.7M | 15.4M | 23.0M | 28.9M | 30.8M | 31.5M | 24.3M | 24.4M | 25.3M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 1.30B | 1.66B | 937.1M | 1.24B | 1.44B | 853.0M | 890.7M | 858.5M | 614.4M | 619.1M |
| Accounts payable | 18.4M | 16.6M | 9.78M | 18.6M | 16.7M | 17.7M | 21.9M | 17.9M | 22.8M | 17.1M |
| Current liabilities | 82.2M | 81.2M | 68.0M | 62.6M | 59.8M | 94.4M | 92.9M | 93.5M | 94.9M | 88.4M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 40.2M | 57.0M | 72.0M | 85.7M | 97.1M | 105.2M | 113.7M | |||
| Total liabilities | 104.1M | 122.2M | 126.1M | 137.9M | 145.8M | 453.5M | 250.2M | 170.9M | 238.9M | 260.5M |
| Shareholders' equity | 1.19B | 1.54B | 811.0M | 1.10B | 1.29B | 399.5M | 640.5M | 687.5M | 375.5M | 358.6M |
| Shares outstanding | 58.4M | 57.2M | 55.9M | 55.0M | 54.3M | 69.3M | 68.4M | 58.2M | 48.8M | 42.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -373.0M | -389.8M | -296.1M | -309.5M | -407.3M | -290.8M | -370.6M | -304.4M | -285.2M | 38.6M |
| Capital spending | -4.32M | -1.69M | -999.0K | -4.88M | -5.74M | -14.1M | -12.0M | -6.99M | -4.63M | -9.91M |
| Free cash flow | -377.3M | -391.5M | -297.1M | -314.4M | -413.1M | -304.9M | -382.6M | -311.4M | -289.9M | 28.6M |
| Cash from investing | 377.2M | 363.4M | 239.6M | 243.3M | 1.25B | 75.7M | 91.4M | -273.8M | -57.9M | -119.3M |
| Cash from financing | 8.68M | 14.4M | 5.43M | 2.35M | -765.8M | 261.5M | 289.6M | 546.0M | 285.1M | 169.8M |
| Dividends paid | -37.3M | 0 | 0 | |||||||
| Share buybacks | 0 | 2.68M | -802.5M | 11.3M | 289.7M | 546.0M | 285.1M | 169.8M | ||
| Change in cash | 12.9M | -12.0M | -51.1M | -63.9M | 75.7M | 46.5M | 10.4M | -32.2M | -58.0M | 89.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 18, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Feb 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 12, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 28, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 8, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 7, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 13, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 13, 2025 | Results | SEC |
| 8-K · Current report | Feb 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jan 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 8, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 7, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Agios Pharmaceuticals, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 59,809,651
- Fully diluted
- 59,809,651
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 59,809,651 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 59,809,651 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Nelsen Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past) | Director · Jul 23, 2013 – Mar 3, 2017 · Past |
| Ian T. Clark Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past) | Director · Dec 30, 2016 – May 20, 2022 · Past |
| John M. Maraganore Other companies: City Therapeutics, Inc. (Executive Chair · Since at least Oct 19, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2021); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); ProKidney Corp. (Director · Jul 11, 2022 – Jun 29, 2023 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past) | Director · Jul 23, 2013 – Dec 31, 2022 · Past |
| Douglas G Cole Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Jan 2, 2019 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past) | Director · Jul 23, 2013 – Aug 10, 2016 · Past |
| Cynthia Smith Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Protara Therapeutics, Inc. (Director · Since at least Jan 29, 2021); Spero Therapeutics, Inc. (Director · Since at least Mar 19, 2019); Akebia Therapeutics, Inc. (Senior Vice President, Market Access and Commercial Development · Since at least Aug 28, 2018); Dicerna Pharmaceuticals Inc (Director · Aug 13, 2018 – Dec 28, 2021 · Past); Alpine Immune Sciences Inc (Director · Nov 1, 2016 – Nov 1, 2016 · Past); ZS Pharma Inc (Chief Commercial Officer · Jun 17, 2014 – Dec 17, 2015 · Past) | Independent Director · Since at least Aug 11, 2022 |
| Jeffrey Capello Other companies: Neogen Corporation (Director · Since at least Sep 2, 2022); Biogen Inc. (EVP & Chief Financial Officer · Dec 11, 2017 – Feb 12, 2020 · Past); Decoy Therapeutics Inc. (Director · Apr 1, 2015 – Jul 26, 2017 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Jul 4, 2018 · Past); Boston Scientific Corporation (EVP & Chief Financial Officer · Jun 16, 2008 – Nov 27, 2013 · Past); Sirtris Pharmaceuticals Inc (Director · Jan 2, 2008 – Jan 2, 2008 · Past); Revvity, Inc. (SVP & CFO · Jan 31, 2006 – Jan 29, 2008 · Past) | Independent Director · Since at least Jun 13, 2023 |
| Perry A Karsen Other companies: LENZ Therapeutics, Inc. (Director · Jan 13, 2021 – Jul 19, 2023 · Past); Jiya Acquisition Corp (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – May 3, 2023 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Dec 17, 2020 · Past); OncoMed Pharmaceuticals Inc (Director · Jan 4, 2016 – Apr 23, 2019 · Past); Voyager Therapeutics, Inc. (Director · Nov 10, 2015 – Jun 13, 2019 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past) | Director · Jul 23, 2013 – Jun 23, 2015 · Past |
| David Schenkein Other companies: Regeneron Pharmaceuticals, Inc. (Director · Since at least Sep 8, 2023); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past); Foghorn Therapeutics Inc. (General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past) | Director · Jul 23, 2013 – Jun 20, 2024 · Past |
| Jacqualyn A. Fouse Other companies: Madrigal Pharmaceuticals, Inc. (Director · Since at least Mar 10, 2025); Incyte Corporation (Director · Since at least Nov 14, 2017); Perrigo Company plc (Director · Nov 6, 2012 – May 4, 2016 · Past); Celgene Corporation (see remarks, Director · Sep 27, 2010 – Feb 14, 2017 · Past); Dick's Sporting Goods Inc (Director · Sep 15, 2010 – Mar 22, 2020 · Past); Bunge Limited (Chief Financial Officer · Jul 23, 2007 – Sep 2, 2010 · Past) | Director · Since at least Dec 3, 2017 |
| Kevin P Starr Other companies: MyoKardia Inc (Director · Oct 28, 2015 – Mar 7, 2018 · Past); Global Blood Therapeutics Inc (Director · Aug 11, 2015 – Aug 17, 2015 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Jun 15, 2023 · Past); Larimar Therapeutics, Inc. (Director · Jun 18, 2014 – Sep 24, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2017 · Past); Human Genome Sciences Inc (Director · May 3, 2007 – Jul 10, 2007 · Past) | Director · Jul 23, 2013 – Feb 19, 2015 · Past |
All 40 people
| Person | Seat |
|---|---|
| Paul J. Clancy Other companies: Sionna Therapeutics, Inc. (Chair · Since at least Feb 6, 2025); Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021); EXACT Sciences Corporation (Director · Since at least Mar 18, 2021); Incyte Corporation (Director · Since at least Jan 20, 2015); Alexion Pharmaceuticals Inc (EVP, Chief Financial Officer · Jul 10, 2017 – Jul 11, 2019 · Past); Biogen Inc. (Executive VP and CFO · Aug 13, 2007 – Apr 25, 2017 · Past) | Director · Sep 24, 2013 – Jun 21, 2022 · Past |
| Steve L. Hoerter Other companies: MBX Biosciences, Inc. (Chairman, President and CEO, Director · Since at least Apr 7, 2025); C4 Therapeutics, Inc. (Director · Since at least Nov 19, 2024); ORIC Pharmaceuticals, Inc. (Board Member, Chairman and CEO of MBX Biosciences · Since at least Aug 13, 2021); Constellation Pharmaceuticals Inc (Director · Sep 4, 2018 – Jul 15, 2021 · Past); Deciphera Pharmaceuticals LLC (President and CEO, Director · May 17, 2018 – Jun 11, 2024 · Past); Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Mar 5, 2015 · Past) | Chief Commercial Officer · Feb 16, 2016 – Mar 1, 2019 · Past |
| Brian Goff Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Jun 13, 2024); Alexion Pharmaceuticals Inc (EVP & Chief Commercial Officer · Jun 1, 2017 – Jul 21, 2021 · Past); Baxalta Inc (EVP and President, Hematology · Jun 30, 2015 – Jun 3, 2016 · Past); Idenix Pharmaceuticals Inc (Director · Mar 27, 2012 – Mar 27, 2012 · Past) | Chief Executive Officer · Since at least Aug 8, 2022 |
| Jay Backstrom Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Disc Medicine, Inc. (Director · Dec 29, 2022 – Dec 29, 2022 · Past); Scholar Rock Holding Corporation (CHIEF EXECUTIVE OFFICER, Director · Sep 20, 2022 – Mar 10, 2025 · Past); Acceleron Pharma Inc (EVP, Research and Development · Dec 10, 2019 – Nov 19, 2021 · Past) | Independent Director · Since at least Jul 8, 2025 |
| Maykin Ho Other companies: Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 17, 2021); Kyntra Bio, Inc. (Director · Since at least Dec 5, 2018); PAREXEL International Corp (Director · Aug 26, 2015 – Sep 29, 2017 · Past) | Independent Director · Since at least Jun 23, 2015 |
| Andrew Hirsch Other companies: C4 Therapeutics, Inc. (President and Chief Executive Officer, Director · Since at least Oct 1, 2020); Editas Medicine, Inc. (Board Member · Since at least May 30, 2017); BIND Therapeutics Inc (PRESIDENT & CEO, Director · Sep 19, 2013 – Jun 22, 2015 · Past) | Chief Financial Officer · Sep 19, 2016 – Apr 22, 2020 · Past |
| David Scadden Other companies: Editas Medicine, Inc. (Director · Since at least Feb 5, 2019); Carisma Therapeutics, Inc. (Director · Jun 30, 2024 – Jul 1, 2024 · Past); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past) | Independent Director · Since at least May 27, 2017 |
| Kaye I Foster-Cheek Other companies: Prime Medicine, Inc. (Director · Since at least Oct 19, 2022); Onyx Pharmaceuticals Inc (SVP, Global Human Resources · Sep 30, 2010 – Oct 1, 2013 · Past); Johnson & Johnson (VP, Human Resources · Feb 13, 2006 – Dec 31, 2009 · Past) | Director · Since at least Dec 9, 2014 |
| Adams Catherine Owen Other companies: ACADIA Pharmaceuticals Inc. (Chief Executive Officer, Director · Since at least Sep 23, 2024); OptiNose (Director · Jul 29, 2020 – Jun 6, 2024 · Past) | Director · Since at least Jun 13, 2023 |
| Jonathan Biller Other companies: Vertex Pharmaceuticals Incorporated (EVP and Chief Legal Officer · Since at least Sep 19, 2022); Celgene Corporation (EVP AND GENERAL COUNSEL · Jul 3, 2018 – Nov 20, 2019 · Past) | Chief Financial Officer · Dec 3, 2019 – Mar 1, 2022 · Past |
| Bruce D. Car Other companies: Biohaven Ltd. (Chief Innovation Officer · Since at least Sep 28, 2022) | Chief Scientific Officer · Jan 6, 2020 – Mar 1, 2022 · Past |
| Carman Alenson Other companies: Prime Medicine, Inc. (See Remarks · Since at least Oct 19, 2022) | Principal Accounting Officer · Nov 7, 2016 – Jun 21, 2021 · Past |
| Cecilia Jones Other companies: LogicBio Therapeutics Inc (Chief Financial Officer · Jan 11, 2021 – Mar 1, 2022 · Past) | Chief Financial Officer · Since at least Sep 26, 2022 |
| Glenn Goddard Other companies: Intellia Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 29, 2018 – Mar 1, 2024 · Past) | Senior Vice President, Finance · Jul 23, 2013 – Feb 16, 2016 · Past |
| John Duncan Higgons Other companies: Jounce Therapeutics Inc (Director · Jan 26, 2017 – Jun 24, 2022 · Past) | Chief Operating Officer · Jul 23, 2013 – Jan 4, 2016 · Past |
| Kaye Foster Other companies: Prime Medicine, Inc. (Board Member · Since at least Nov 4, 2026) | Independent Director · Since at least Nov 5, 2026 |
| Krishnan Viswanadhan Other companies: CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023) | Chief Strategy and Operations Officer · Since at least Mar 5, 2025 |
| Rahul Ballal Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Mar 11, 2020) | Independent Director · Since at least Aug 11, 2022 |
| Sarah Gheuens Other companies: Viridian Therapeutics, Inc. (Chief Medical Officer, Head of R&D, Agios Pharmaceuticals · Since at least Sep 21, 2023) | Chief Medical Officer, Head of R&D · Since at least Sep 1, 2021 |
| Scott Biller Other companies: Foghorn Therapeutics Inc. (Executive Venture Partner, Google Ventures (GV) · Since at least Oct 22, 2020) | Chief Scientific Officer · Jul 23, 2013 – Jun 11, 2019 · Past |
| Catherine Owen | Independent Director · Since at least Nov 5, 2026 |
| Contacts:Investor ContactMorgan Sanford | Vice President, Investor Relations Agios · Since at least Mar 2, 2026 |
| Darrin Miles | Chief Commercial Officer · Jan 16, 2021 – May 14, 2021 · Past |
| Ellen Lopresti | Chief People Officer · Since at least Nov 5, 2026 |
| Jackie Fouse | Independent Director · Since at least Nov 5, 2026 |
| James William Burns | Chief Legal Officer · Since at least Jan 1, 2022 |
| Jim Burns | Chief Legal Officer · Since at least Apr 6, 2026 |
| Richa Poddar | Chief Commercial Officer · Dec 6, 2021 – Oct 15, 2022 · Past |
| Theodore James Washburn Jr | Principal Accounting Officer · Since at least Aug 1, 2021 |
| Tsveta Milanova | Chief Commercial Officer · Since at least Jan 3, 2023 |
Log in to ask 6ix AI your own questions about Agios Pharmaceuticals, Inc.